PTGX
Price
$52.83
Change
+$0.54 (+1.03%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
3.24B
20 days until earnings call
TNXP
Price
$42.36
Change
+$4.00 (+10.43%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
282.22M
31 days until earnings call
Interact to see
Advertisement

PTGX vs TNXP

Header iconPTGX vs TNXP Comparison
Open Charts PTGX vs TNXPBanner chart's image
Protagonist Therapeutics
Price$52.83
Change+$0.54 (+1.03%)
Volume$19.27K
Capitalization3.24B
Tonix Pharmaceuticals Holding
Price$42.36
Change+$4.00 (+10.43%)
Volume$6.86K
Capitalization282.22M
PTGX vs TNXP Comparison Chart in %
Loading...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TNXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PTGX vs. TNXP commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a Hold and TNXP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (PTGX: $52.83 vs. TNXP: $42.36)
Brand notoriety: PTGX and TNXP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTGX: 63% vs. TNXP: 106%
Market capitalization -- PTGX: $3.24B vs. TNXP: $282.22M
PTGX [@Biotechnology] is valued at $3.24B. TNXP’s [@Biotechnology] market capitalization is $282.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTGX’s FA Score shows that 1 FA rating(s) are green whileTNXP’s FA Score has 2 green FA rating(s).

  • PTGX’s FA Score: 1 green, 4 red.
  • TNXP’s FA Score: 2 green, 3 red.
According to our system of comparison, PTGX is a better buy in the long-term than TNXP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTGX’s TA Score shows that 4 TA indicator(s) are bullish while TNXP’s TA Score has 4 bullish TA indicator(s).

  • PTGX’s TA Score: 4 bullish, 4 bearish.
  • TNXP’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both PTGX and TNXP are a good buy in the short-term.

Price Growth

PTGX (@Biotechnology) experienced а +3.48% price change this week, while TNXP (@Biotechnology) price change was +19.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.19%. For the same industry, the average monthly price growth was +16.32%, and the average quarterly price growth was +20.67%.

Reported Earning Dates

PTGX is expected to report earnings on Nov 05, 2025.

TNXP is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+10.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($3.24B) has a higher market cap than TNXP($282M). PTGX has higher P/E ratio than TNXP: PTGX (67.72) vs TNXP (0.12). PTGX YTD gains are higher at: 36.852 vs. TNXP (28.441). PTGX has higher annual earnings (EBITDA): 30.1M vs. TNXP (-66.23M). PTGX has more cash in the bank: 574M vs. TNXP (132M). TNXP has less debt than PTGX: TNXP (563K) vs PTGX (11.4M). PTGX has higher revenues than TNXP: PTGX (208M) vs TNXP (10M).
PTGXTNXPPTGX / TNXP
Capitalization3.24B282M1,149%
EBITDA30.1M-66.23M-45%
Gain YTD36.85228.441130%
P/E Ratio67.720.1256,961%
Revenue208M10M2,080%
Total Cash574M132M435%
Total Debt11.4M563K2,025%
FUNDAMENTALS RATINGS
PTGX vs TNXP: Fundamental Ratings
PTGX
TNXP
OUTLOOK RATING
1..100
193
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
47100
SMR RATING
1..100
5498
PRICE GROWTH RATING
1..100
4738
P/E GROWTH RATING
1..100
210
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TNXP's Valuation (27) in the Pharmaceuticals Other industry is somewhat better than the same rating for PTGX (78) in the Biotechnology industry. This means that TNXP’s stock grew somewhat faster than PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (47) in the Biotechnology industry is somewhat better than the same rating for TNXP (100) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew somewhat faster than TNXP’s over the last 12 months.

PTGX's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for TNXP (98) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew somewhat faster than TNXP’s over the last 12 months.

TNXP's Price Growth Rating (38) in the Pharmaceuticals Other industry is in the same range as PTGX (47) in the Biotechnology industry. This means that TNXP’s stock grew similarly to PTGX’s over the last 12 months.

PTGX's P/E Growth Rating (2) in the Biotechnology industry is in the same range as TNXP (10) in the Pharmaceuticals Other industry. This means that PTGX’s stock grew similarly to TNXP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTGXTNXP
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 8 days ago
78%
Bullish Trend 1 day ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 1 day ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TNXP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NIPNF28.10N/A
N/A
NEC Corp
PGID0.01N/A
N/A
Peregrine Industries, Inc.
QURT0.60N/A
N/A
Quarta-Rad, Inc.
SLFPY10.78N/A
N/A
Aberdeen Group PLC
MAOIF24.99N/A
N/A
Manitou DF